Chromoblastomycosis is a subcutaneous fungal infection caused by the traumatic inoculation of the skin with pigmented saprophytic moulds. Although infection is rarely fatal, it is characteristically chronic and can be complicated by lymphatic damage and malignant transformation. Despite a variety of treatment modalities, which are often combined and include long courses of antifungals, surgical excision and destructive physical therapies, it remains one of the most difficult deep mycotic infections to eradicate.
SharmaNL, SharmaRC, GroverPS, GuptaML, SharmaAK, MahajanVK. Chromoblastomycosis in India. Int J Dermatol2002;41:16–2
4.
BonifazA, Carrasco-GerardE, SaúlA. Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses2001;44:1–7
5.
AblizP, FukushimaK, TakizawaK, NishimuraK. Specific oligonucleotide primers for identification of Cladophialophora carrionii, a causative agent of chromoblastomycosis. J Clin Microbiol2004;42:404–7
6.
de AndradeTS, CuryAE, de CastroLG, HirataMH, HirataRD. Rapid identification of Fonsecaea by duplex polymerase chain reaction in isolates from patients with chromoblastomycosis. Diagn Microbiol Infect Dis2007;57:267–72
7.
Oberto-PerdigónL, RomeroH, Pérez-BlancoM, Apitz-CastroR. An ELISA test for the study of the therapeutic evolution of chromoblastomycosis by Cladophialophora carrionii in the endemic area of Falcon State, Venezuela. Rev Iberoam Micol2005;22:39–43[Spanish]
VitaleRG, Perez-BlancoM, De HoogGS. In vitro activity of antifungal drugs against Cladophialophora species associated with human chromoblastomycosis. Med Mycol2009;47:35–40
10.
CaligiorneRB, ResendeMA, MelilloPH, PelusoCP, CarmoFH, AzevedoV. In vitro susceptibility of chromoblastomycosis and phaeohyphomycosis agents to antifungal drugs. Med Mycol1999;37:405–9
EsterreP, InzanCK, RamarcelER, Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study. Br J Dermatol1996;134(Suppl. 46):33–6
13.
BonifazA, SaúlA, Paredes-SolisV, AraizaJ, Fierro-AriasL. Treatment of chromoblastomycosis with terbinafine: experience with four cases. J Dermatolog Treat2005;16:47–51
14.
UngpakornR, ReangchainamS. Pulse itraconazole 400 mg daily in the treatment of chromoblastomycosis. Clin Exp Dermatol2006;31:245–7
15.
GuptaAK, TabordaPR, SanzovoAD. Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol2002;40:529–34
16.
YuJ, LiR, ZhangM, LiuL, WanZ. In vitro interaction of terbinafine with itraconazole and amphotericin B against fungi causing chromoblastomycosis in China. Med Mycol2008;46:745–7
17.
ZhangJM, XiLY, ZhangH, Synergistic effects of terbinafine and itraconazole on clinical isolates of Fonsecaea monophora. Eur J Dermatol2009;19:451–5
18.
LopezCF, AlvarengaRJ, CisalpinoEO, ResendeMA, OliveiraLG. Six years experience in treatment of chromomycosis with 5-fluorocytosine. Int J Dermatol1978;17:414–8
19.
NegroniR, TobonA, BustamanteB, Shikanai-YasudaMA, PatinoH, RestrepoA. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev Inst Med Trop Sao Paulo2005;47:339–46
20.
BonifazA, Martinez-SotoE, Carrasco-GerardE, PenicheJ. Treatment of chromoblastomycosis with itraconazole, cryosurgery, and a combination of both. Int J Dermatol1997;36:542–7
21.
CastroLG, PimentelER, LacazCS. Treatment of chromomycosis by cryosurgery with liquid nitrogen: 15 years' experience. Int J Dermatol2003;42:408–12
22.
TagamiH, GinozaM, ImaizumiS, Urano-SuehisaS. Successful treatment of chromoblastomycosis with topical heat therapy. J Am Acad Dermatol1984;10:615–9
23.
HirumaM, KawadaA, YoshidaM, KouyaM. Hyperthermic treatment of chromomycosis with disposable chemical pocket warmers. Report of a successfully treated case, with a review of the literature. Mycopathologia1993;122:107–14
